620 related articles for article (PubMed ID: 25341119)
1. Overcoming tumor-mediated immunosuppression.
Schlößer HA; Theurich S; Shimabukuro-Vornhagen A; Holtick U; Stippel DL; von Bergwelt-Baildon M
Immunotherapy; 2014; 6(9):973-88. PubMed ID: 25341119
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
Saleh R; Elkord E
Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
[TBL] [Abstract][Full Text] [Related]
3. Targeting regulatory T cells in tumors.
Liu C; Workman CJ; Vignali DA
FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
[TBL] [Abstract][Full Text] [Related]
4. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Senant M; Giusti D; Weiss L; Dragon-Durey MA
Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
[TBL] [Abstract][Full Text] [Related]
6. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.
Arina A; Corrales L; Bronte V
Semin Immunol; 2016 Feb; 28(1):54-63. PubMed ID: 26872631
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells in cancer; can they be controlled?
Adeegbe DO; Nishikawa H
Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
[No Abstract] [Full Text] [Related]
8. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
Stewart TJ; Smyth MJ
Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.
Tay C; Tanaka A; Sakaguchi S
Cancer Cell; 2023 Mar; 41(3):450-465. PubMed ID: 36917950
[TBL] [Abstract][Full Text] [Related]
10. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.
Wei F; Wang D; Wei J; Tang N; Tang L; Xiong F; Guo C; Zhou M; Li X; Li G; Xiong W; Zhang S; Zeng Z
Cell Mol Life Sci; 2021 Jan; 78(1):173-193. PubMed ID: 32654036
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
12. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?
Zito Marino F; Ascierto PA; Rossi G; Staibano S; Montella M; Russo D; Alfano R; Morabito A; Botti G; Franco R
Expert Opin Biol Ther; 2017 Jun; 17(6):735-746. PubMed ID: 28318336
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
[TBL] [Abstract][Full Text] [Related]
14. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
16. [Cancer immunotherapy. Importance of overcoming immune suppression].
Malvicini M; Puchulo G; Matar P; Mazzolini G
Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs.
Whiteside TL; Mandapathil M; Szczepanski M; Szajnik M
Bull Cancer; 2011 Feb; 98(2):E25-31. PubMed ID: 21339097
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
Poggi A; Musso A; Dapino I; Zocchi MR
Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
[TBL] [Abstract][Full Text] [Related]
19. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Badalamenti G; Fanale D; Incorvaia L; Barraco N; Listì A; Maragliano R; Vincenzi B; Calò V; Iovanna JL; Bazan V; Russo A
Cell Immunol; 2019 Sep; 343():103753. PubMed ID: 29395859
[TBL] [Abstract][Full Text] [Related]
20. [Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].
Shimazu Y; Nishikawa H
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1057-61. PubMed ID: 25248887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
